























































































































































































































































































































































































































































































































































































































































































































































































































































































































































Smad 2/3 Smad 1/5/8 
PP
Smad 4       
P
Smad 4       
P ON 
Smad 2/3 Smad 1/5/8 
BMP 




















































































































































TNM Classification Dukes’ 
Classification 
Stage 0 Carcinoma in situ 
Stage I Tumour invasion of the submucosa of the 
bowel only (T1, N0, M0) 
A 
Tumour invasion of the muscle layer of the 
bowel wall, muscularis propria (T2, N0,M0) 
 
B1 
Stage II Tumour invasion, into the outer lining of the 
bowel wall (T3, N0, M0) 
B2 
Tumour invaded through the outer lining of the 
bowel wall (T4, N0, M0) 
 
B2 




4 or more lymph nodes containing cancer cells  
(T1-2, N2, M0) 
 
C1 




4 or more lymph nodes containing cancer cells 
(T3-4, N2, M0) 
 
C2 




































































































































































































































-  advanced/metastatic CRC 
-  Fit for first line chemotherapy 
-  Consent to biomarker analysis 
Standard chemotherapy for 16 weeks; stable or responding 
disease 
Biomarker analysis on 
FFPE tumour blocks 

























SOC P P P P P P P 
Consent and randomisation 
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Bulk tumour cell 















































































































































































































































































































































































































2D cell monolayer 
Organoids from normal, 































































































































































HEPES	(1M)	 	 10mM	 10mM	 10mM	
GlutaMAX	(100X)	 	 2mM	 2mM	 2mM	
N2	(100X)	 	 	 1X	 1X	
B27	(50X)	 	 	 1X	 1X	








TGF-ß	modulator	 	 	 100ng/ml	














Fungizone*	 Anti-fungal	agent	 	 2µl/ml	 2µl/ml	








































































Ki67	 Proliferation	 Millipore		 AB9260	 1/100	 Rabbit	
Caspase	3	 Apoptosis	 R&D	 AF385	 1/100	 Rabbit	
Beta-catenin	 Wnt	signaling	 BD		 610154	 1/250	 Mouse	
Cyclin	B1	 Proliferation	 Santa	Cruz	 SC-752	 1/50	 Rabbit	
Lgr5	 Intestinal	
stem	cell	
BD	 562733	 1/250	 Rat	
Cytokeratin	
20	



















































































Edge	detec(on	sensi(vity	 75.4	 32.9	 32.9	 32.9	 59.7	 48.5	
Center	detec(on	sensi(vity	 64.2	 43.5	 50.8	 50.8	 97.2	 71.5	
SoD	colony	lower	diameter	(µm)	 40	 60	 35	 55	 25	 30	
SoD	colony	upper	diameter	(µm)	 1000	 600	 600	 600	 70	 600	
Minimum	center	to	center	
sepera(on	 40	 60	 35	 55	 25	 30	
Smoothing	 3	 3	 3	 3	 3	 3	
Circularity	factor	 62	 80	 62	 62	 52	 82	
Edge	distance	threshold	 0.88	 0.74	 0.74	 0.74	 0.74	 0.81	
Number	of	spokes	 32	 32	 32	 32	 32	 32	












Colony	diameter	minimum	(µm)	 40um	 70	 55	 55	 10	 30	
Colony	diameter	maximum	(µm)	 1000um	 375	 375	 375	 70	 375	
Colony	minimum	intensity	
(	op(cal	density)	 0.1	 0.05	 0.05	 0.05	 0.01	 0.01	
Colony	maximum	intensity	
(op(cal	density)	 0.32	 10	 10	 10	 10	 10	
Good	edge	factor	 0.57	 0.06	 0.06	 0.06	 0.06	 0.06	
Borders	from	centeroids	 yes	 yes	 yes	 yes	 yes	 yes	
Merge	overlapping	objects	 yes	 yes	 yes	 yes	 yes	 yes	
Overlap	threshold	 0.67	 0.75	 0.75	 0.75	 0.75	 0.75	














































































































































GSK12118473	 Dabrafenib	 BRAF	inhibitor	 DMSO	 Stratech	Ltd	 0.12	 500	 2	
	 Panitumumab	 EGFR	inhibitor	 PBS	 clinic	 0.02	 62.5	 2	
GSK1120212	 Trame*nib	 MEK	inhibitor	 DMSO	 Stratech	Ltd	 0.06	 250	 2	
PIK3CA	
muta*on	 	 Salicylic	acid	 unclear	 DMSO	 Sigma	 19	 5000	 2	
KRAS/p53	







inhibitor	 DMSO	 Stratech	Ltd	 8	 1250	 2	
ATM	





inhibitor	 DMSO	 Tocris	 19	 10000	 2	
MSC2501490A	 TNKS	inhibitor	 DMSO	 Merck	Serono	 4	 1250	 2	
	MSC2572070A	 TNKS	inhibitor	 DMSO	 Merck	Serono	 0.80	 250	 2	















500.00	 250.00	 62.50	 750.00	 312.50	 562.50	 812.50	
250.00	 125.00	 31.25	 375.00	 156.25	 281.25	 406.25	
125.00	 62.50	 15.63	 187.50	 78.13	 140.63	 203.13	
62.50	 31.25	 7.81	 93.75	 39.06	 70.31	 101.56	
31.25	 15.63	 3.91	 46.88	 19.53	 35.16	 50.78	
15.63	 7.81	 1.95	 23.44	 9.77	 17.58	 25.39	
7.81	 3.91	 0.98	 11.72	 4.88	 8.79	 12.70	
3.91	 1.95	 0.49	 5.86	 2.44	 4.39	 6.35	
1.95	 0.98	 0.24	 2.93	 1.22	 2.20	 3.17	
0.98	 0.49	 0.12	 1.46	 0.61	 1.10	 1.59	
0.49	 0.24	 0.06	 0.73	 0.31	 0.55	 0.79	
0.24	 0.12	 0.03	 0.37	 0.15	 0.27	 0.40	














































































































































































































































































vivo	as	well	 as	 response	 to	 therapeutic	agents,	whilst	 simultaneously	 retaining	 the	
usability	of	high	throughput	2D	cultures	to	facilitate	the	testing	of	a	high	number	of	
compounds,	 is	 instrumental	 for	 drug	 discovery	 purposes.	 In	 order	 to	 establish	
organoids	as	a	 successful	 in	 vitro	modelling	 system,	 their	 setup	and	use	had	 to	be	
optimised	 to	 ensure	 both	 relevance	 to	 patient	 tumours,	 as	well	 as	 reproducibility	
within	 robust	assay	 formats,	 compatible	 for	 the	analysis	of	 complex	3D	structures.		
Here,	we	show	the	expansion	of	a	cohort	of	patient-derived	organoids	cultures	from	
primary	CRC	 tumour	material	 based	on	 culture	 systems	 that	 have	previously	 been	








(ii) To	 optimise	 suitable	 growth	 conditions	 to	 facilitate	 maximal	 organoid	
expansion	in	culture	which	retain	key	characteristics	of	parental	tumours	




























































34	 69	 M	 Transverse	
Colon	
Well/Moderate	 A	 T2N0Mx	
36	 77	 F	 Rectum	 Well/Moderate	 B	 T3N0Mx	
38	 64	 M	 Sigmoid	
Colon	
Well/Moderate	 C1	 T3N1Mx	
48	 43	 M	 Rectum	 Poor	 C2	 T4N2M1	
49	 75	 M	 Lower	
Sigmoid	
Well/Moderate	 C1	 T3N1Mx	
50	 75	 M	 Rectum	 Poor	 C2	 T3N1Mx	
72	 83	 F	 Caecum	 Well/Moderate	 B	 T3N0Mx	
73	 60	 M	 Sigmoid	
Colon	
Well/Moderate	 B	 T3N0Mx	
75	 76	 F	 Caecum	 Poor	 C1	 T3N1Mx	







































































































Full 7+ Full 7+ 
1000 cell fragments per 
50 µl matrigel 
2000 cell fragments per 




















































































































































































































































ROCK- inhibitor (10 µM)  








Pieces Single cells + 
ROCKi 































































































































































































































































































































































































































































































































100 400 1000 
Number of cells seeded/ µl Matrigel 
Day 0 Day 7 
Cell Titer Glo 3D 
Reagent addition 
(A) (B) (C) 
F. 
200 500 
































































































































































































0 156 312 625 
 5
 
2500 1250 78 39 19 9 
7 












Day 0 Day 7 Day 3 
5-Fluorouracil 
addition 




































































































































































































































































Maximum projection of 
single organoids 
Mask settings applied to 
single organoid 
Mark single cells within an 
organoid (Hoechst) 
Mark positively stained 
cells within an organoid 












































































































 (Bi)  (Bii) 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Dabrafenib Trametinib Panitumumab 
Dabrafenib+ 
Trametinib 


















































































































































age acquisition of organoid z-stacks  
Im
age segm
entation per channel, per z-stack 
O



































alisation of features by z-score 
P
C
A on the z-scores to extract variable features 
M
ahalanobis distance m
etric applied based on 




etric plotted per treatm
ent dose 
com










ingle cell suspension 



























 (B) Iso 72














































































































































































































Whilst	 previous	 chapters	 have	 described	 the	 utility	 of	 organoids	 as	 a	 medium-
throughput	system	to	assess	clinically	 relevant	compounds,	 this	 thesis	also	aims	to	
establish	organoids	as	a	useful	 tool	 in	a	drug	discovery	setting.	 In	order	 to	explore	
this,	 multi-parametric	 phenotypic	 screening	 (OcellO)	 of	 organoids	 were	 used	 to	






















To	 fully	 investigate	 the	 capacity	 of	 organoids	 to	 demonstrate	 on-target	 effects	 of	
novel	 compounds,	 three	 compounds	 in	 development	 with	Merck	 Serono	 with	 log	
fold	 changes	 in	 EC50	 values	 (i.e	 effective	 concentration	 to	 limit	 growth	 of	 50%	 of	
cells)	were	tested	within	the	established	organoid	cohort	previously	described.		EC50	
values	 of	 each	 compound	 (MSC2501490A,	 MSC2572070A,	 MSC2524070)	 were	
provided	by	Merck	Serono,	as	detected	by	a	luminex	assay	against	AXIN2,	indicating	
EC50	values	of	300	nM,	36nM	and	3nM,	respectively.	This	2D	cell-based	assay	utilises	
AXIN2	 stabilisation	 as	 a	 readout,	 as	 AXIN2	 is	 a	 target	 of	 TNKS1/2.	 Upon	

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































16 NOD/SCID/ γ-irradiated 
mice 










































































































































































































































































































































Inhibition of compensatory 
mechanisms, inhibition of overall 
pathway activity 
Combination Therapy 






















Single agent Therapy 



























































































































































































































































































































































































































Tumour formation Organoids in DMSO Control 
Conditions 
Delayed tumour formation 
ê  LGR5	
ê  ASCL2  
é  KRT20	
	
Organoids in TNKSi 
conditions 
Transplantation into NOD/
SCID/ γ-irradiated mice 
 
Transplantation into NOD/



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Iso 75 Iso 75 Iso 72 Iso 72 Iso 50 Iso 50 
0 (0.1% DMSO) 15 















ADV-DMEM/F12	 	 Invitrogen	 12634-028	 1X	 1X	
Penicillin/	
Streptocymcin		
	 Invitrogen	 15140-122	 100	U/ml	 100	U/ml	
HEPES	(1M)	 	 Invitrogen	 15630-056	 10mM	 10mM	
GlutaMAX	(100X)	 	 Invitrogen	 35050-079	 2mM	 2mM	
N2	(100X)	 	 Invitrogen	 17502-048	 1X	 1X	















	 Peprotech	 250-38	 	 100ng/ml	
A-83-01	 Alk4/5/7	
inhibitor	














	 	 	 	 10%	(v/v)	
Fungizone*	 	 Invitrogen	 	 2µl/ml	 2µl/ml	
Y-27632*	 ROCK	
inhibitor	
R&D	 129830-38-2	 10µM	 10µM		
